Osteoprotic patients with rheumatoid arthritis
Conditions
Interventions
The selection criteria is based on which treatment each patient wants to take
Minodronate group: oral intake 50mg per month
Minodronate plus active vitamin D group: oral intake 50mg minodronate per m
Sponsors
Department of Orthopaedic Surgery Shinshu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Rheumatoid arthritis compliactated with steoporosis, aged over 20. 2. The patients who desire to take the above treatment 3. The patients who agree to perform this study after sufficient informed consent
Exclusion criteria
Exclusion criteria: 1. The patients who are allergic to minodronate or eldecalcitol 2. The patients with hypercalcemia before treatment 3. The patients whom we judge as inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Value changes of bone mineral density (lumber as well as bilateral proximal hip) before treatment and at 24 months after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequencies of adverse effects (at 6, 12, and 24 months after treatment) Value chanes of the following at 6, 12, and 24 months after treatment 1. Bone mineral density (lumber as well as bilateral proximal hip) values 2. Values of bone turnover markers 3. Values of serum vitamin D 4. Values of serum PTH | — |
Countries
Japan
Contacts
Public ContactYukio Nakamura
Shinshu University School of Medicine Department of Orthopaedic Surgery
Outcome results
None listed